Jürgen Koscielny

Jürgen Koscielny

Auto-generated profile, based on publicly available information

Jürgen Koscielny

Institute for Transfusion Medicine, Charite University Hospital Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
CDCarl-Erik Dempfle
Carl-Erik Dempfle
JKJürgen Koscielny
Jürgen Koscielny
Edelgard Lindhoff-LastEdelgard Lindhoff-Last
Edelgard Lindhoff-Last
BLBirgit Linnemann
Birgit Linnemann
IBIrene Bux-Gewehr
Irene Bux-Gewehr
AHAndreas Heinken
Andreas Heinken
We analyzed data for women who received fondaparinux for ≥7 days during pregnancy. The study retrospectively included women who received fondaparinux pre-, peri- and/or postpartum for ≥7 days for prophylaxis/venous thromboembolism (VTE) treatment at German specialist centers (2004-2010). Data on pregnancy, VTE risk factors, anticoagulant treatment, pregnancy outcome and adverse events were extracted from medical records. 120 women (mean age 31.5 years) were included. Among 84 women with prior pregnancies, 41.0% had ≥1 abortion. Anticoagulation was indicated for prophylaxis in 92.5% cases, including 82.5% women with an elevated VTE risk (82.8% thrombophilia, 34.2% VTE history). All women received low-molecular-weight heparin (LMWH) as first-line therapy; 3 also unfractionated heparin. Treatment changed to fondaparinux, due to heparin allergy (41.7%) or heparin-induced thrombocytopenia (10.0%). Fondaparinux was generally well tolerated. Adverse events included bleeding events (n = 5), abortion (n = 2), premature births (n = 2), stillbirth (n = 1), arrested labors (n = 2), injection site erythema (n = 4) and unspecified drug hypersensitivity (n = 6). No VTE events or increased liver enzymes occurred during treatment. In this retrospective study, fondaparinux was effective and well tolerated. Trial registration: ClinicalTrials.gov NCT01004939.

22 July 2025 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
NCNike Annika Christensen
Nike Annika Christensen
NFNicolas Feltgen
Nicolas Feltgen
MHMaren Horn
Maren Horn
SNSabine Naxer
Sabine Naxer
COChristian van Oterendorp
Christian van Oterendorp
MSMichael P. Schittkowski
Michael P. Schittkowski
Background/Aims Clear guidelines for managing patients on antiplatelet (AP) or anticoagulant (AC) therapy undergoing oculoplastic surgery are lacking. This study investigates bleeding risk factors and evaluates the effectiveness of a standardised bleeding risk assessment in extraocular surgery. Methods In this prospective study, a standardised questionnaire (SQ) was employed to gather patients’ bleeding histories. Associations between SQ scores and preoperative/demographic factors (AP/AC use, age, sex, comorbidities), and surgical factors (blood pressure, surgery type, primary vs revision surgery, anaesthesia type, duration, pain management) were assessed. A scoring system quantified bleeding severity. Patients were monitored postoperatively for 24 hours (eyelid procedures) to 3 or 4 days (orbital/nasolacrimal surgery). Results A total of 324 patients (aged 18–92) were included (252 eyelid, 56 orbital and 16 nasolacrimal surgeries). 87 patients were using AP, AC and/or herbal supplements. Severe bleeding occurred in 35 patients, four required revision surgery, though none suffered permanent damage. Bleeding complications were significantly associated with higher SQ scores (p=0.048), acetylsalicylic acid use in eyelid surgery (p=0.038), diabetes mellitus (p=0.016), renal disease (p=0.044), general anaesthesia (p=0.001) and longer surgery duration (p=0.007). Local anaesthesia, AC use and systolic hypertension were not significantly associated with bleeding risk. Conclusion The SQ is a valuable tool for assessing bleeding risk in oculoplastic patients. Findings support future multicentre studies to develop evidence-based perioperative guidelines for AP and AC management. Limitations include cohort heterogeneity, small sample size, non-blinded design and subjective bleeding scores affecting comparability.

1 January 2015 in Hamostaseologie
Verified
Journal Article
Closed access
PDF file
ERE. Rutkauskaite
E. Rutkauskaite
JKJ. Koscielny
J. Koscielny
The doses of these drugs are barely tested and the potential clinical thromboembolic risk must be taken into account. Despite the widespread use of NOAC (non vitamin-K dependent oral anticoagulants) and recommendations of regulatory agencies and first consensus meeting on handling the bleeding situation under NOAC, especially in hospitals without a large hemostatic focus, uncertainty still exists. In case of mild bleeding from a clinical perspective, the medical care of these patients and the delay of the next dose or discontinuation is advised. A special laboratory analysis is indicated i.e. in case of known higher grade liver and kidney failure, which can cause a prolonged elimination of NOAC. The administration of factor concentrates is not indicated in this situation. In case of moderate to severe bleeding, the primary measures focus on the stabilization of the heart and circulatory function and parallel on the treatment depending on the localization of the bleeding source. According to experience, mostly gastrointestinal bleeding occurs under the NOAC, which should be supplied endoscopically. In life-threatening bleeding in addition to the measures of hemodynamic stabilization usually a special haemostasis management is required, which should be mainly clinically oriented. After the assessment of bleeding predictor, the time of the last dose and the dose of NOAC should be learned, but other causes of bleeding, including Fibrinolysis, should be excluded or treated. Subsequently, routinely promptly rivaroxaban and/ or apixaban sensitive thromboplastin time (Quick’s value) and a thrombin time (thrombin- poor calibrator) for qualitative assessment can be carried out because only very few hospitals have specific tests (anti-Xa measurements, bovine thrombin), which could be promptly done. If there is a significant deviation from the normal range or to present preliminary value of particular patient, an effect of NOAC most likely exists. In life-threatening bleeding the use of factor concentrates (procoagulants) is indicated. The first-line therapy should be PPSB. Only in exceptional cases, especially when dabigatran is taken, the use of aPPSB (FEIBA®) for prompt haemostasis can be considered. The haemostasis should be always clinically estimated and not according to coagulation tests. The use of rFVIIa (Novo Seven®) shows different results in the bleeding therapy (reversal) under Dabigatran. The doses of these drugs are barely tested and the potential clinical thromboembolic risk must be taken into account. The current concepts of the newly developed antidotes are not clinically validated. First prospective, clinical registries have been started. Trotz des breiten Einsatzes von NOAK (nicht Vitamin-K-abhängige Antikoagulanzien) und Empfehlungen der Zulassungsbehörden und erster Konsensusmeetings zum Umgang in der Blutungssituation mit NOAK besteht insbesondere in Krankenhäusern ohne hämo - staseologischen Schwerpunkt eine große Handlungsunsicherheit. Bei aus klinischer Sicht leichten Blutungen ist die medizinische Überwachung dieser Patienten und die Verzögerung der nächsten Einnahme oder das passagere Absetzen anzuraten. Eine spezielle Laboranalytik ist u.a. besonders bei bekannter hochgradiger Leber- und Niereninsuffizienz, die eine verlängerte Elimination der NOAK verursachen können, angezeigt. Die Gabe von Faktorenkonzentraten ist in dieser Situation kontraindiziert. Bei mittelschweren bis schweren Blutungen richten sich die primären Maßnahmen auf die Stabilisierung der Herz- und Kreislauffunktion sowie parallel auf die Behandlung je nach Lokalisation des Blutungsherdes. Bei den NOAK können dies erfahrungsgemäß meist gastrointestinale Blutungen sein, welche endoskopisch versorgt werden sollten. Bei vital bedrohlichen Blutungen ist neben den Maßnahmen der hämodynamischen Stabilisierung in aller Regel ein spezielles Hämostasemanagement erforderlich, welches vorwiegend klinisch orientiert sein sollte. Nach der Beurteilung von Blutungsprädiktoren sollte der Zeitpunkt der letzten Einnahme und die NOAK-Dosis in Erfahrung gebracht werden, aber auch andere Blutungsursachen, z. B. Hyperfibrinolyse, sind auszuschließen bzw. zu behandeln. Anschließend kann zeitnah routinemäßig eine Rivaro- xaban bzw. Apixaban empfindliche Thromboplastinzeit (Quick-Wert) sowie eine Thrombinzeit (thrombinverdünnter Kalibrator) zur qualitativen Beurteilung durchgeführt werden, da den wenigsten Krankenhäusern spezifische Tests (Anti-Xa-Messung, bovine Thrombinzeit) zeitnah zur Verfügung stehen. Ist eine deutliche Abweichung zum Normbereich oder zum vorliegenden Vorwert des jeweiligen Patienten erkennbar, ist eine Wirkung von NOAK mit großer Wahrscheinlichkeit gegeben. Bei vital bedrohlichen Blutungen ist dann der Einsatz von Faktorenkonzentraten (Prokoagulatoren) indiziert. Die Therapie der ersten Wahl sollte PPSB sein. Nur in absoluten Ausnahmefällen, insbesondere bei Dabigatran, kann der Einsatz von aPPSB (FEIBA®) für eine zeitnahe Blutstillung, die stets klinisch und nicht durch einen Gerinnungstest zu beurteilen ist, erwogen werden. Der Einsatz von rFVIIa (Novo Seven®) zeigt bei Blutungen unter Dabigatran unterschiedliche Ergebnisse. Die Dosierungen dieser Präparate sind klinisch kaum erprobt und das potentielle thromboembolische Risiko ist zu berücksichtigen. Die aktuellen Konzepte der neu entwickelten Antidots sind klinisch nicht erprobt. Erste prospektive Register sind gestartet. 1 nicht Vitamin- K-abhängige Antikoagulanzien

15 February 1999 in Gefässchirurgie
Verified
Journal Article
Closed access
PDF file
APAxel Pruss
Axel Pruss
JKJ. Koscielny
J. Koscielny
RLR. Latza
R. Latza
BMB. Mayer
B. Mayer
CSChristine Stier
Christine Stier
HKH. Kiesewetter
H. Kiesewetter

1 January 1995 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Closed access
PDF file
HKH. Kiesewetter
H. Kiesewetter
FJFriedrich Jung
Friedrich Jung
TRT. Rother
T. Rother
JKJ. Koscielny
J. Koscielny
CMC. Mrowietz
C. Mrowietz
EWE. Wenzel
E. Wenzel
The aim of this double blind placebo controlled crossover study is to show that apart from decreasing blood pressure felodipine improves microcirculation. 30 patients with essential hypertension and manifest microangiopathy were included. No patients

1 January 1991
Verified
Book Chapter
Closed access
PDF file
JKJ. Koscielny
J. Koscielny
HKH. Kiesewetter
H. Kiesewetter
FJFriedrich Jung
Friedrich Jung
AHA. Haaß
A. Haaß